Epstein-Barr Virus Infection Clinical Trial
Official title:
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine, mRNA-1195, in Healthy Adults 18 to 55 Years of Age
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy adults (18 to 55 years of age).
There will be 2 sequential parts to the study: - Participants will be enrolled in Part A of the study first, which will only enroll those participants who are EBV-seropositive at Screening. - Part B will enroll only those participants who are EBV-seronegative at Screening. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05683834 -
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
|
Phase 1/Phase 2 | |
| Completed |
NCT02499302 -
Mental Training for CFS Following EBV Infection in Adolescents
|
N/A | |
| Terminated |
NCT01805037 -
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04645147 -
Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection
|
Phase 1 | |
| Active, not recruiting |
NCT05164094 -
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults
|
Phase 1 | |
| Active, not recruiting |
NCT02135042 -
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
|
Phase 2/Phase 3 |